Compositions and methods for treating SARS-CoV-2 infections
The present application relates to methods and compositions and methods for treating viral infections, especially those caused by SARS-CoV-2. In one aspect, a method of treatment comprises administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a multipartite SARS-CoV-2-inhibiting peptide comprising a secretion modulating region (VI-SMR) peptide from HIV-1 Nef in combination with a cell-penetrating peptide (CPP) domain, a Clusterin (Clu)-binding peptide (Clu-BP) domain, a mitochondrial targeting (Mito-T) peptide domain, an anti-fusogenic (AF) peptide domain, a viral attachment inhibitor (VAI) domain or combination thereof, optionally where the SARS-CoV-2-inhibiting peptide is pegylated and/or modified with one or more hydrophobic domains.
1. A method for treating a SARS-CoV-2 infection, comprising:
administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a virus-inhibiting secretion modifying region (VI-SMR) peptide comprising an SMR peptide from HIV-1 Nef in combination with a cell penetrating peptide (CPP), a Clusterin-binding peptide (Clu-BP), or both.
2. The method of claim 1 , wherein the SMR peptide comprises the amino acid sequence of VGFPVAAVGFPV (SEQ ID NO: 2), VGFPVAAVGFPVGRKKRRQRRRPPQ (SEQ ID NO: 4) or VGFPVAAVGFPVAAHPLSKHPYWSQPAAHPLSKHPYWSQP (SEQ ID NO: 48).
3. The method of claim 1 , wherein the VI-SMR peptide comprises an anti-SARS-CoV-2 anti-fusogenic (AF) peptide, an anti-SARS-CoV-2 viral attachment inhibitor (VAI) peptide, a mitochondrial targeting (Mito-T) peptide, or combination thereof.
4. The method of claim 1 , wherein the VI-SMR peptide is pegylated, conjugated to a fatty acid, or both.
5. The method of claim 1 , wherein the pharmaceutical composition comprises a dimeric or multimeric VI-SMR peptide.
6. The method of claim 1 , wherein the pharmaceutical composition is administered in combination with one or more antiviral agents targeting SARS-2-CoV-2.
7. The method of claim 1 , wherein the VI-SMR peptide is loaded into an exosome that is administered into the subject infected with SARS-CoV-2.
8. A method for treating a SARS-CoV-2 infection, comprising:
administering to a subject in need of such treatment a pharmaceutical composition comprising an effective amount of an anti-SARS-CoV-2 peptide comprising an SMR peptide from HIV-1 Nef fused to a CPP, Clu-BP, or both, optionally wherein the anti-SARS-CoV-2 peptide is administered in combination with a mortalin inhibitor, an anti-SARS-CoV-2 AF peptide, an anti-SARS-CoV-2 VAI peptide, or combination thereof.
9. The method of claim 8 , wherein the pharmaceutical composition comprising the anti-SARS-CoV-2 peptide is administered in combination with an AF peptide or VAI peptide,
wherein the anti-SARS-CoV-2 peptide is administered independent of the AF peptide or the VAI peptide or wherein the anti-SARS-CoV-2 peptide is administered as a single peptide fused to the anti-SARS-CoV-2 peptide or the VI-SMR peptide.
10. The method of claim 8 , wherein the anti-SARS-CoV-2 peptide is pegylated, conjugated to a fatty acid, or both.
11. The method of claim 8 , wherein the pharmaceutical composition comprises a dimeric or multimeric anti-SARS-CoV-2 peptide.
12. The method of claim 8 , wherein the pharmaceutical composition is administered in combination with one or more antiviral agents inhibiting SARS-2-CoV-2 infections.